{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.189","value":"-0.038"},{"groupId":"OG001","spread":"0.245","value":"-0.046"}]}],"title":"Cycle 4 (n=166, 145)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.212","value":"-0.054"},{"groupId":"OG001","spread":"0.148","value":"0.003"}]}],"title":"Cycle 10 (n=71, 45)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.214","value":"-0.062"},{"groupId":"OG001","spread":"0.085","value":"-0.012"}]}],"title":"Cycle 16 (n=47, 25)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.290","value":"-0.129"},{"groupId":"OG001","spread":"0.280","value":"-0.144"}]}],"title":"End of Treatment (n=166, 190)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"166"},{"groupId":"OG001","value":"190"}],"units":"Participants"}],"description":"The EQ-5D is a self-reported, 5-dimension (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) questionnaire related to the participant's current health state. Each question was scored using a 3 level scale (no problems, some problems, or extreme problems). EQ-5D health state was defined by combining responses from each of the 5 dimensions into a weighted health-state index score according to the United Kingdom (UK) population based algorithm where 0 = death and 1 = perfect health.","dispersionType":"Standard Deviation","groups":[{"description":"Ramucirumab 8 mg/kg IV infusion every 2 weeks. BSC: Palliative and supportive care for disease-related symptoms and toxicity associated with treatment as deemed medically necessary and appropriate in the opinion of the investigator.","id":"OG000","title":"Ramucirumab (IMC-1121B) + BSC"},{"description":"Placebo: 8 mg/kg IV infusion every 2 weeks. BSC: Palliative and supportive care for disease-related symptoms and toxicity associated with treatment as deemed medically necessary and appropriate in the opinion of the investigator.","id":"OG001","title":"Placebo + BSC"}],"paramType":"MEAN","populationDescription":"Randomized participants who had an EQ-5D score at baseline and the specified time points.","reportingStatus":"POSTED","timeFrame":"Baseline, Prior to infusion on Day 1 of Cycle 4, Cycle 10, and Cycle 16 (14-day cycles), end of treatment (up to 34 months)","title":"Change From Baseline in European Quality of Life Questionnaire-5 Dimensions (EQ-5D) Health State Score","type":"SECONDARY","unitOfMeasure":"units on a scale"}